| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.
|
Cancer Cell
|
2005
|
7.99
|
|
2
|
Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias.
|
Blood
|
2006
|
1.83
|
|
3
|
A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance.
|
Blood
|
2013
|
1.38
|
|
4
|
Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants.
|
Blood
|
2010
|
1.32
|
|
5
|
Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells.
|
Mol Cancer Ther
|
2008
|
1.23
|
|
6
|
Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells.
|
Mol Cancer Ther
|
2007
|
1.18
|
|
7
|
Purification and characterization of a transmembrane domain-deleted form of lecithin retinol acyltransferase.
|
Biochemistry
|
2003
|
1.13
|
|
8
|
Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells.
|
Blood
|
2008
|
1.09
|
|
9
|
Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity.
|
Gastroenterology
|
2006
|
1.09
|
|
10
|
Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells.
|
Blood
|
2008
|
1.01
|
|
11
|
In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells.
|
Clin Cancer Res
|
2013
|
0.89
|
|
12
|
Preclinical evaluation of a novel SIRT1 modulator SRT1720 in multiple myeloma cells.
|
Br J Haematol
|
2011
|
0.89
|
|
13
|
Antileukemic Effects of Novel First- and Second-Generation FLT3 Inhibitors: Structure-Affinity Comparison.
|
Genes Cancer
|
2010
|
0.87
|
|
14
|
Discovery and characterization of novel mutant FLT3 kinase inhibitors.
|
Mol Cancer Ther
|
2010
|
0.84
|
|
15
|
Reversible resistance induced by FLT3 inhibition: a novel resistance mechanism in mutant FLT3-expressing cells.
|
PLoS One
|
2011
|
0.84
|
|
16
|
Spectroscopic and thermodynamic studies on the binding of sanguinarine and berberine to triple and double helical DNA and RNA structures.
|
J Biomol Struct Dyn
|
2003
|
0.84
|